SAN DIEGO--(BUSINESS WIRE)--Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN) announced today its majority owned subsidiary, Entest BioMedical unit (OTCBB: ENTB), has filed a patent application for the use of adipose derived stem cells in the treatment of Chronic Obstructive Pulmonary Disease (COPD). BMSN is excited with the progress achieved by Entest BioMedical, Inc. (OTCBB: ENTB) in identifying diseases it believes will be treatable through Stem Cell Therapy.
